US 12,643,939 B2Granted

Antibody to Epstein Barr virus and uses thereof

AssigneeThe Council of the Queensland Institute of Medical Research

InventorsRajiv Khanna, Kristine Hua

Life of this patent

Estimating the term…

Abstract

A recombinant, humanized antibody or antibody fragment that is capable of at least partly preventing or inhibiting Epstein Barr Virus gp350 binding to a human cell. The antibody may be useful for passively immunizing humans against Epstein Barr Virus and/or treating or preventing Epstein Barr Virus-associated diseases, disorders or conditions. The antibody or antibody fragment may also be used to detect Epstein Barr Virus.

Claims15

Dependent claims

A recombinant, human or humanized antibody or antibody fragment that is capable of at least partly reducing or inhibiting Epstein Barr Virus (EBV) gp350 binding to a human cell, which comprises six complementarity determining regions (CDR)s comprising a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 selected from:

Clone
CDR
SEQ ID NO:
B8
HCDR1
1 (Chothia), 37 (AbM), 73
(Kabat), 109
HCDR2
2 (Chothia), 38 (AbM), 74
(Kabat), 110
HCDR3
3 (Chothia), 39 (AbM), 75
(Kabat), 111
LCDR1
19 (Chothia), 55 (AbM), 91
(Kabat), 127
LCDR2
20 (Chothia), 56 (AbM), 92
(Kabat), 128
LCDR3
21 (Chothia), 57 (AbM), 93
(Kabat), 129;
or
A11
HCDR1
4 (Chothia), 40 (AbM), 76
(Kabat), 112
HCDR2
5 (Chothia), 41 (AbM), 77
(Kabat), 113
HCDR3
6 (Chothia), 42 (AbM), 78
(Kabat), 114
LCDR1
22 (Chothia), 58 (AbM), 94
(Kabat), 130
LCDR2
23 (Chothia), 59 (AbM), 95
(Kabat), 131
LCDR3
24 (Chothia), 60 (AbM), 96
(Kabat), 132 (Contact)
E10
HCDR1
7 (Chothia), 43 (AbM), 79
(Kabat), 115 (Contact)
HCDR2
8 (Chothia), 44 (AbM), 80
(Kabat), 116 (Contact)
HCDR3
9 (Chothia), 45 (AbM), 81
(Kabat), 117 (Contact)
LCDR1
25 (Chothia), 61 (AbM), 97
(Kabat), 133 (Contact)
LCDR2
26 (Chothia), 62 (AbM), 98
(Kabat), 134 (Contact)
LCDR3
27 (Chothia), 63 (AbM), 99
(Kabat), 135 (Contact)
B7
HCDR1
10 (Chothia), 46 (AbM), 82
(Kabat), 118 (Contact)
HCDR2
11 (Chothia), 47 (AbM), 83
(Kabat), 119 (Contact)
HCDR3
12 (Chothia), 48 (AbM), 84
(Kabat), 120 (Contact)
LCDR1
28 (Chothia), 64 (AbM), 100
(Kabat), 136 (Contact)
LCDR2
29 (Chothia), 65 (AbM), 101
(Kabat), 137 (Contact)
LCDR3
30 (Chothia), 66 (AbM), 102
(Kabat), 138 (Contact)
D7
HCDR1
13 (Chothia), 49 (AbM), 85
(Kabat), 121 (Contact)
HCDR2
14 (Chothia), 50 (AbM), 86
(Kabat), 122 (Contact)
HCDR3
15 (Chothia), 51 (AbM), 87
(Kabat), 123 (Contact)
LCDR1
31 (Chothia), 67 (AbM), 103
(Kabat), 139 (Contact)
LCDR2
32 (Chothia), 68 (AbM), 104
(Kabat), 140 (Contact)
LCDR3
33 (Chothia), 69 (AbM), 105
(Kabat), 141 (Contact)
C10
HCDR1
16 (Chothia), 52 (AbM), 88
(Kabat), 124 (Contact)
HCDR2
17 (Chothia), 53 (AbM), 89
(Kabat), 125 (Contact)
HCDR3
18 (Chothia), 54 (AbM), 90
(Kabat), 126 (Contact)
LCDR1
34 (Chothia), 70 (AbM), 106
(Kabat), 142 (Contact)
LCDR2
35 (Chothia), 71 (AbM), 107
(Kabat), 143 (Contact)
LCDR3
36 (Chothia), 72 (AbM), 108,
144 (Contact).

115 more elements

An antibody or antibody fragment comprising a heavy chain (VH) variable region sequence and a light chain (VL) variable region sequence selected from:

Clone
Chain
SEQ ID NO:
B8
VH
145
VL
151
A11
VH
146
VL
152
E10
VH
147
VL
153
B7
VH
148
VL
154
D7
VH
149
VL
155
C10
VH
150
VL
156
wherein the VH variable region sequence according to any one of SEQ ID NOs:
145-150 has an amino acid sequence at least 90% identical thereto, and wherein the light chain (VL) variable region sequence according to any one of SEQ ID NOS:
151-156 or an amino acid sequence at least 90% identical thereto;
wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 animo acid sequences are selected from:
Clone
CDR
SEQ ID NO:
B8
HCDR1
1 (Chothia), 37 (AbM), 73
(Kabat), 109
HCDR2
2 (Chothia), 38 (AbM), 74
(Kabat), 110
HCDR3
3 (Chothia), 39 (AbM), 75
(Kabat), 111
LCDR1
19 (Chothia), 55 (AbM), 91
(Kabat), 127
LCDR2
20 (Chothia), 56 (AbM), 92
(Kabat), 128
LCDR3
21 (Chothia), 57 (AbM), 93
(Kabat), 129;
or
A11
HCDR1
4 (Chothia), 40 (AbM), 76
(Kabat), 112
HCDR2
5 (Chothia), 41 (AbM), 77
(Kabat), 113
HCDR3
6 (Chothia), 42 (AbM), 78
(Kabat), 114
LCDR1
22 (Chothia), 58 (AbM), 94
(Kabat), 130
LCDR2
23 (Chothia), 59 (AbM), 95
(Kabat), 131
LCDR3
24 (Chothia), 60 (AbM), 96
(Kabat), 132 (Contact)
E10
HCDR1
7 (Chothia), 43 (AbM), 79
(Kabat), 115 (Contact)
HCDR2
8 (Chothia), 44 (AbM), 80
(Kabat), 116 (Contact)
HCDR3
9 (Chothia), 45 (AbM), 81
(Kabat), 117 (Contact)
LCDR1
25 (Chothia), 61 (AbM), 97
(Kabat), 133 (Contact)
LCDR2
26 (Chothia), 62 (AbM), 98
(Kabat), 134 (Contact)
LCDR3
27 (Chothia), 63 (AbM), 99
(Kabat), 135 (Contact)
B7
HCDR1
10 (Chothia), 46 (AbM), 82
(Kabat), 118 (Contact)
HCDR2
11 (Chothia), 47 (AbM), 83
(Kabat), 119 (Contact)
HCDR3
12 (Chothia), 48 (AbM), 84
(Kabat), 120 (Contact)
LCDR1
28 (Chothia), 64 (AbM), 100
(Kabat), 136 (Contact)
LCDR2
29 (Chothia), 65 (AbM), 101
(Kabat), 137 (Contact)
LCDR3
30 (Chothia), 66 (AbM), 102
(Kabat), 138 (Contact)
D7
HCDR1
13 (Chothia), 49 (AbM), 85
(Kabat), 121 (Contact)
HCDR2
14 (Chothia), 50 (AbM), 86
(Kabat), 122 (Contact)
HCDR3
15 (Chothia), 51 (AbM), 87
(Kabat), 123 (Contact)
LCDR1
31 (Chothia), 67 (AbM), 103
(Kabat), 139 (Contact)
LCDR2
32 (Chothia), 68 (AbM), 104
(Kabat), 140 (Contact)
LCDR3
33 (Chothia), 69 (AbM), 105
(Kabat), 141 (Contact)
C10
HCDR1
16 (Chothia), 52 (AbM), 88
(Kabat), 124 (Contact)
HCDR2
17 (Chothia), 53 (AbM), 89
(Kabat), 125 (Contact)
HCDR3
18 (Chothia), 54 (AbM), 90
(Kabat), 126 (Contact)
LCDR1
34 (Chothia), 70 (AbM), 106
(Kabat), 142 (Contact)
LCDR2
35 (Chothia), 71 (AbM), 107
(Kabat), 143 (Contact)
LCDR3
36 (Chothia), 72 (AbM), 108,
144 (Contact).

152 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/638,125Filed 10 Aug 2018
Priority: AU 201790319710 Aug 2017
Published: US 2020/0255499 A113 Aug 2020
Granted: 2 Jun 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61P 31/22
For DNA viruses: for herpes viruses
C07K 16/085
DNA viruses: orthoherpesviridae , e.g. pseudorabies virus or Epstein-Barr virus
G01N 33/56994
Viruses: herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

US 2020/0255499 A1Pre-grant publication · published 13 Aug 2020
US 12,643,939 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Clone
CDR
SEQ ID NO:
B8
HCDR1
1 (Chothia), 37 (AbM), 73
(Kabat), 109
HCDR2
2 (Chothia), 38 (AbM), 74
(Kabat), 110
HCDR3
3 (Chothia), 39 (AbM), 75
(Kabat), 111
LCDR1
19 (Chothia), 55 (AbM), 91
(Kabat), 127
LCDR2
20 (Chothia), 56 (AbM), 92
(Kabat), 128
LCDR3
21 (Chothia), 57 (AbM), 93
(Kabat), 129;
or
A11
HCDR1
4 (Chothia), 40 (AbM), 76
(Kabat), 112
HCDR2
5 (Chothia), 41 (AbM), 77
(Kabat), 113
HCDR3
6 (Chothia), 42 (AbM), 78
(Kabat), 114
LCDR1
22 (Chothia), 58 (AbM), 94
(Kabat), 130
LCDR2
23 (Chothia), 59 (AbM), 95
(Kabat), 131
LCDR3
24 (Chothia), 60 (AbM), 96
(Kabat), 132 (Contact)
E10
HCDR1
7 (Chothia), 43 (AbM), 79
(Kabat), 115 (Contact)
HCDR2
8 (Chothia), 44 (AbM), 80
(Kabat), 116 (Contact)
HCDR3
9 (Chothia), 45 (AbM), 81
(Kabat), 117 (Contact)
LCDR1
25 (Chothia), 61 (AbM), 97
(Kabat), 133 (Contact)
LCDR2
26 (Chothia), 62 (AbM), 98
(Kabat), 134 (Contact)
LCDR3
27 (Chothia), 63 (AbM), 99
(Kabat), 135 (Contact)
B7
HCDR1
10 (Chothia), 46 (AbM), 82
(Kabat), 118 (Contact)
HCDR2
11 (Chothia), 47 (AbM), 83
(Kabat), 119 (Contact)
HCDR3
12 (Chothia), 48 (AbM), 84
(Kabat), 120 (Contact)
LCDR1
28 (Chothia), 64 (AbM), 100
(Kabat), 136 (Contact)
LCDR2
29 (Chothia), 65 (AbM), 101
(Kabat), 137 (Contact)
LCDR3
30 (Chothia), 66 (AbM), 102
(Kabat), 138 (Contact)
D7
HCDR1
13 (Chothia), 49 (AbM), 85
(Kabat), 121 (Contact)
HCDR2
14 (Chothia), 50 (AbM), 86
(Kabat), 122 (Contact)
HCDR3
15 (Chothia), 51 (AbM), 87
(Kabat), 123 (Contact)
LCDR1
31 (Chothia), 67 (AbM), 103
(Kabat), 139 (Contact)
LCDR2
32 (Chothia), 68 (AbM), 104
(Kabat), 140 (Contact)
LCDR3
33 (Chothia), 69 (AbM), 105
(Kabat), 141 (Contact)
C10
HCDR1
16 (Chothia), 52 (AbM), 88
(Kabat), 124 (Contact)
HCDR2
17 (Chothia), 53 (AbM), 89
(Kabat), 125 (Contact)
HCDR3
18 (Chothia), 54 (AbM), 90
(Kabat), 126 (Contact)
LCDR1
34 (Chothia), 70 (AbM), 106
(Kabat), 142 (Contact)
LCDR2
35 (Chothia), 71 (AbM), 107
(Kabat), 143 (Contact)
LCDR3
36 (Chothia), 72 (AbM), 108,
144 (Contact).

115 more elements

Facts

Application

16/638,125Filed 10 Aug 2018

Priority

AU 201790319710 Aug 2017

Published

US 2020/0255499 A113 Aug 2020

Granted

2 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61P 31/22
For DNA viruses: for herpes viruses
C07K 16/085
DNA viruses: orthoherpesviridae , e.g. pseudorabies virus or Epstein-Barr virus
G01N 33/56994
Viruses: herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies